American Oncology Network Stock Price, News & Analysis

Cancer and Blood Specialists of Arizona (CBSA), a partner practice of American Oncology Network (AONC), announces the addition of Dr. Ronak Rakesh Shah to its physician care team at the Casa Grande clinic. Dr. Shah, a Board-certified medical oncologist and hematologist, brings expertise from his education at Michigan State University and fellowship training at Larkin Community Hospital.

CBSA's team now comprises two medical oncologists, a radiation oncologist, a general surgeon, and three advanced practice providers across two Arizona locations. The practice offers comprehensive cancer care services including diagnosis, treatment, clinical trials, survivorship, and patient support, all accessible locally to minimize patient travel.

American Oncology Network (AON) has partnered with Vantage Health Technologies to enhance cancer care delivery through an AI-enabled value-based care platform. The collaboration will initially implement Vantage's SocialHealth360 solution to improve patient navigation and address Social Determinants of Health (SDoH). The platform is expected to save healthcare professionals 5-8 hours weekly on administrative tasks, reduce provider burnout, and improve patient outcomes while lowering care costs. Future phases will focus on implementing AI solutions for value-based care use-cases.

Florida Oncology and Hematology, a partner practice of American Oncology Network (AON) (OTCQX: AONC), has opened a new location in Cape Coral, Florida. The clinic, located at 326 Del Prado Blvd, Suite 301, welcomes three board-certified medical oncologists: Dr. Magali Van den Bergh (Medical Director), Dr. Venkata Parsa, and Dr. Shivtaj Mann.

The new facility offers comprehensive cancer care services, including an on-site infusion room, in-house lab and pathology services, access to an in-house specialty pharmacy, and support with care coordination and financial counseling. This expansion marks Florida Oncology and Hematology's fifth location in Florida since August 2024, demonstrating the practice's commitment to providing community-based, patient-centered oncology care.

American Oncology Network (OTCQX: AONC), a rapidly expanding community-based oncology practice, has announced its plans to release second quarter 2024 financial results on Wednesday, August 14, 2024, before the market opens. The company will host a conference call and live webcast for investors at 8:30 a.m. Eastern Time on the same day.

To join the call, participants can dial 1-877-704-4453 (US) or 1-201-389-0920 (international) using the passcode 13748211. A replay will be available for one week, accessible by dialing 1-844-512-2921 (US) or 1-412-317-6671 (international) with the Access ID 13748211. The financial results and live webcast will also be available on the company's Investor Relations website at investors.aoncology.com.

American Oncology Network (AON) announced its transition from NASDAQ to the OTCQX Best Market, trading under the symbol AONC. The move aims to enhance transparency and convenience for U.S. investors, brokers, and institutions. CEO Todd Schonherz highlighted the benefits of OTCQX, including adherence to high financial standards and improved trading experiences. Shares and warrants began trading on June 10, 2024, with warrants being listed on OTCQB as AONCW. The company aims to expand its network of oncology practices, offering affordable cancer care nationwide. Financial disclosures and real-time quotes are available on otcmarkets.com.

American Oncology Network (AON) (Nasdaq: AONC) has appointed David Afshar as Chief Financial and Operating Officer. Afshar brings over 25 years of experience in healthcare services, focusing on high-growth environments. His expertise spans M&A, capital markets, and IPOs. CEO Todd Schonherz and CMO Stephen 'Fred' Divers welcomed Afshar, highlighting his potential to drive AON's financial and operational strategies. Afshar aims to enhance accessibility and affordability in cancer care, leveraging his collaborative approach. Previously, Afshar served as CFO for U.S. Heart and Vascular, Aveanna Healthcare, and ApolloMD.

American Oncology Network (AON) announced its decision to delist its Class A common stock and warrants from Nasdaq, effective around June 7, 2024. This decision, recommended by a Special Committee of independent directors, aims to address issues such as the lack of research coverage, an inactive trading market, and high regulatory costs associated with Nasdaq listing. AON will file Form 25 with the SEC on or about May 31, 2024. The company plans to transition its securities to trading on the OTC Markets Group. CEO Todd Schonherz highlighted AON's financial health, boasting over $100 million in cash and a 42% revenue CAGR over the past five years.

American Oncology Network (NASDAQ: AONC) reported a 20% revenue increase in Q1 2024, reaching $364.3 million, driven by a 7.1% rise in patient encounters. They added 17 new providers and expanded into Texas and Maryland.

The company faced a net loss of $24.9 million, up from $1.5 million in Q1 2023, due to increased costs, including $13.3 million in equity-based compensation.

Adjusted EBITDA decreased to $2.0 million from $4.1 million year-over-year. Liquidity stood at $132.7 million, aided by a $48.3 million deferral in drug payments.

American Oncology Network (Nasdaq: AONC) announced a change in the release date for its first quarter 2024 financial results, now set for May 20, 2024, before the market opens. A conference call and live webcast will follow on May 21, 2024, at 8:30 a.m. ET. To join the call, dial 1-877-704-4453 (U.S.) or 1-201-389-0920 (international), with passcode 13746298. A replay will be available until May 28, 2024, by dialing 1-844-512-2921 (U.S.) or 1-412-317-6671 (international), using Access ID 13746298. Additionally, AONC plans to file a Form 12b-25 for an automatic extension on its Form 10-Q quarterly report filing.